The trial achieved the two its Most important endpoints, with semaglutide 2.four mg demonstrating statistically substantial and superior enhancements in liver fibrosis without any worsening of steatohepatitis, in addition to resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH when compared with placebo.1Regime chec